Medical
-
Quince Therapeutics announced that it has agreed to acquire Orphai Therapeutics (formerly AI Therapeutics, formerly LAM Therapeutics) and its LAM-001 inhaled dry powder rapamycin (sirolimus) for $115 million up front and up to an additional… Read more . . .
-
Vertex has stopped a Phase 1/2 study of VX-522 inhaled RNA therapy for the treatment of cystic fibrosis and has ceased development of the product, the company said in its most recent report of financial… Read more . . .
-
Insilico Medicine, which has facilities in the US and China, said that an IND for a Phase 1 PK trial of rentosertib (ISM001-055) inhalation solution has been cleared by the CDE. The company said that… Read more . . .
-
Oragenics said that it has initiated a Phase 2a trial of ONP-002, a dry powder intranasal neurosteroid, for the treatment of mild traumatic brain injury in Australia after receiving approval from the Human Research Ethics… Read more . . .
-
According to Dompé, researchers at the Agostino Gemelli IRCCS University Hospital in Rome, Italy have initiated a Phase 2 trial of Dompé’s intranasal formulation of cenegermin-bkbj, a recombinant human nerve growth factor, in patients with… Read more . . .
-
According to United Therapeutics, the Phase 3 TETON-1 trial of nebulized Tyvaso treprostinil inhalation solution in patients with idiopathic pulmonary fibrosis met its primary endpoint, demonstrating a 130.1 mL change in absolute FVC from baseline to… Read more . . .
-
According to Tonix Pharmaceuticals, researchers at Erasmus University Medical Center have initiated a Phase 1 study of Tonix’s TNX-1900 intranasal potentiated oxytocin in healthy female volunteers as a proof of concept for the potential use… Read more . . .
-
In April 2025, Avalyn Pharma announced plans to advance its AP02 nintedanib inhalation solution into a Phase 2 trial in patients with idiopathic pulmonary fibrosis. Avalyn has now announced the initiation of the Phase 2… Read more . . .
-
According to Insmed, the Phase 3b ENCORE study of once-daily Arikayce amikacin liposome inhalation suspension plus azithromycin and ethambutol in patients with newly diagnosed Mycobacterium avium complex (MAC) lung infection met its primary endpoint. The study demonstrated a… Read more . . .
-
Interna Therapeutics has announced that under an agreement with the University of Oxford researchers led by Oxford’s Helen McShane will conduct a Phase 2a study of the company’s intranasal molecular nano-motor (MNM)-siRNA drug against SARS-CoV-2.… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland